Skip to main content
Clinical Trials/NCT01441622
NCT01441622
Completed
Not Applicable

In-hospital Assessment of the New Medical Device AL539 Developed for the Home Monitoring of Continuous Positive Airway Pressure (CPAP) Treatment in Patients With Obstructive Sleep Apnea Syndrome by Comparison With Respiratory Polygraphy

Air Liquide Santé International1 site in 1 country20 target enrollmentJune 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obstructive Sleep Apnea Syndrome
Sponsor
Air Liquide Santé International
Enrollment
20
Locations
1
Primary Endpoint
CPAP treatment duration
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

Continuous Positive Airway Pressure (CPAP) is the standard treatment in patients with Obstructive Sleep Apnea Syndrome (OSAS).

The goal of the study is to evaluate CPAP treatment duration recorded by the AL539 during attended in-hospital polysomnography in patients with Obstructive Sleep Apnea Syndrome.

Detailed Description

Patients are patients with sleep apnea predominantly obstructive, with CPAP for at least 2 months, and requiring in-hospital night polygraphic record control. The medical device was developed to determine: * the duration of use of CPAP by the patient, * the persistence of any respiratory abnormalities during treatment. These two parameters are used to ensure that treatment is done correctly. The use of the AL539 is expected to improve the home-monitoring of ventilation with CPAP.

Registry
clinicaltrials.gov
Start Date
June 2011
End Date
April 2012
Last Updated
11 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Air Liquide Santé International
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Sleep apnea predominantly obstructive
  • CPAP for at least 2 months and requiring in-hospital night polygraphic record
  • Written informed consent form
  • Able to read and write in French

Exclusion Criteria

  • Ventilator with two levels of pressure
  • CPAP breathing circuit non-compatible with the AL539
  • Chronic respiratory disease
  • Psychotropic treatment which may influence the respiratory parameters
  • Acute rhinitis or acute nasopharyngitis
  • Moderate or severe chronic heart failure
  • CHEYNE-STOKES respiration
  • Body mass index (BMI) \> 40
  • Pregnant woman or woman of childbearing potential with a positive urinary pregnancy test
  • Uncontrolled progressive disease

Outcomes

Primary Outcomes

CPAP treatment duration

Time Frame: up to 12 hours

Continous Positive Airway Pressure treatment duration

Secondary Outcomes

  • Apneas-Hypopneas(up to 12 hours)
  • Mean pressure(up to 12 hours)
  • Mean Flow(up to 12 hours)

Study Sites (1)

Loading locations...

Similar Trials